Two major strategic collaborations announced in July and August 2026 underscore the intensifying race to capture value from ...
Building trust in cost-effective treatments Two biosimilars—Zimrixby (rituximab-cdxx) and Garzulys (insulin aspart-fsan)—received US Food and Drug Administration ...
Sun Pharmaceutical Industries has completed the syndication of debt financing for its US$11.75 billion acquisition of US-based Organon & Co, with State Bank of India (SBI) joining 10 international ...
On 23 July 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for ...
The Brazilian Health Regulatory Agency (ANVISA) published on 29 June 2026, Informative Note 1/2026/GGBIO, providing clarifications on the evaluation of comparative pharmacokinetic (PK) studies for ...
La Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA) publicó el 29 de junio de 2026 la Nota Informativa 1/2026/GGBIO, que ofrece aclaraciones sobre la evaluación de los estudios ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results